Literature DB >> 2828894

Human monoclonal antibodies to Pseudomonas aeruginosa produced by EBV-transformed cells.

H Suzuki1, Y Okubo, M Moriyama, M Sasaki, Y Matsumoto, T Hozumi.   

Abstract

Numerous lymphoblastoid cell lines (LCLs) which secreted antibodies against Pseudomonas aeruginosa (all Fisher's immunotypes and Homma's immunotype 1) were established by Epstein-Barr virus (EBV)-transformation of lymphocytes. Five LCLs were established as long-term culture lines and their properties were determined. These LCLs produced monoclonal antibodies to Fisher's immunotype 1 and 4 and Homma's immunotype 1, and their immunoglobulin classes were IgM, IgG, and IgA. We found that three monoclonal antibodies (G3-1, H7-2, and E10-1) among them successfully protected mice from the corresponding immunotype of P. aeruginosa infection. Their protective dose (PD50) values were 0.5, 2.6, and 3.1 micrograms immunoglobulin/mouse. These human monoclonal antibodies against P. aeruginosa prepared by EBV-transformation method will be a valuable aid for the treatment for severe P. aeruginosa infections.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2828894     DOI: 10.1111/j.1348-0421.1987.tb01328.x

Source DB:  PubMed          Journal:  Microbiol Immunol        ISSN: 0385-5600            Impact factor:   1.955


  2 in total

1.  Phage display and bacterial expression of a recombinant Fab specific for Pseudomonas aeruginosa serotype O6 lipopolysaccharide.

Authors:  N L Tout; J S Lam
Journal:  Clin Diagn Lab Immunol       Date:  1997-03

2.  A protective human monoclonal antibody directed to the outer core region of Pseudomonas aeruginosa lipopolysaccharide.

Authors:  M Terashima; I Uezumi; T Tomio; M Kato; K Irie; T Okuda; S Yokota; H Noguchi
Journal:  Infect Immun       Date:  1991-01       Impact factor: 3.441

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.